Drugs@FDA document
LEVULAN Letter · NDA 020965 SUPPL-17
Drugs@FDA document · SUN PHARM INDS INC · May 10, 2022
Key facts
| Drug name | LEVULAN |
|---|---|
| Document type | Letter |
| Application | NDA020965 |
| Submission | SUPPL-17 |
| Company | SUN PHARM INDS INC |
| Document date | May 10, 2022 |
| FDA document | accessdata.fda.gov |
At a glance
- Labeling-Package Insert Document categories
- 10–99 Documents for this application
- 1–9 USP chapters cited in this application's documents
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA documents
Drugs@FDA posts the letters, labels, reviews and other documents behind each drug application and supplement. Orca1 indexes every document's full text and flags complete response letters.
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA application documents · Source date: